Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization

International Journal of Molecular Medicine

Volumn 32, Issue 4, 2013, Pages 938-944

  Putranto, Endy Widya ^a   Murata, Hitoshi ^a   Yamamoto, Ken Ichi ^a   Kataoka, Ken ^b   Yamada, Hidenori ^c   Futami, Jun Ichiro ^c   Sakaguchi, Masakiyo ^a   Huh, Nam Ho ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY OF SCIENCE   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cationization; Cell death; Cell migration; Receptor for advanced glycation end products; S100B; Toll interleukin 1 receptor domain containing adaptor protein

Indexed keywords

ADAPTOR PROTEIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; POLYETHYLENEIMINE; PROTEIN CDC42; PROTEIN S100B; TOLL INTERLEUKIN RECEPTOR 1 DOMAIN CONTAINING ADAPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROTECTION; CONTROLLED STUDY; EMBRYO; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; APOPTOSIS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HEK293 CELLS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; PEPTIDES; PHOSPHORYLATION; POLYETHYLENEIMINE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN-1; S100 PROTEINS; SIGNAL TRANSDUCTION;

EID: 84883423336     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1467     Document Type: Article

References (40)

1. Neeper M, Schmidt AM, Brett J, et al: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992.
2. Schmidt AM, Yan SD, Yan SF and Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99-111, 2000.
3. Schmidt AM, Mora R, Cao R, et al: The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269: 9882-9888, 1994.
4. Hofmann MA, Drury S, Fu C, et al: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901, 1999.
5. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R and Rauvala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275: 40096-40105, 2000.
6. Leclerc E, Fritz G, Weibel M, Heizmann CW and Galichet A: S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 282: 31317-31331, 2007.
7. Li J, Qu X and Schmidt AM: Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem 273: 30870-30878, 1998.
8. Yan SD, Chen X, Fu J, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691, 1996.
9. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH and Chuang LY: Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK?49F cells. J Cell Biochem 81: 102-113, 2001.
10. Yeh CH, Sturgis L, Haidacher J, et al: Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50: 1495-1504, 2001.
11. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA and Schmidt AM: Activation of the receptor for advanced glycation end products triggers a p21(ras)'dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814, 1997.
12. Huttunen HJ, Kuja-Panula J and Rauvala H: Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 277: 38635-38646, 2002.
13. Brett J, Schmidt AM, Yan SD, et al: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712, 1993.
14. Beccafico S, Riuzzi F, Puglielli C, et al: Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. Age 33: 523-541, 2011.
15. Srikanth V, Maczurek A, Phan T, et al: Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 32: 763-777, 2011.
16. Maczurek A, Shanmugam K and Münch G: Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann NY Acad Sci 1126: 147-151, 2008.
17. Koyama H and Nishizawa Y: AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest 40: 623-635, 2010.
18. Reiniger N, Lau K, McCalla D, et al: Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 59: 2043-2054, 2010.
19. Wu L, Ma L, Nicholson LF and Black PN: Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 105: 329-336, 2011.
20. Ramasamy R, Yan SF and Schmidt AM: Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann NY Acad Sci 1243: 88-102, 2011.
21. Su XD, Li SS, Tian YQ, Zhang ZY, Zhang GZ and Wang LX: Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes. Arch Med Res 42: 596-601, 2011.
22. Leclerc E, Heizmann CW and Vetter SW: RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen Physiol Biophys 28: F65-F75, 2009.
23. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ and Rauvala H: Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811, 2002.
24. Arumugam T, Ramachandran V, Gomez SB, Schmidt AM and Logsdon CD: S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res 18: 4356-4364, 2012.
25. Abe R, Shimizu T, Sugawara H, et al: Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 122: 461-467, 2004.
26. Arumugam T, Ramachandran V and Logsdon CD: Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 98: 1806-1818, 2006.
27. Sakaguchi M, Murata H, Yamamoto K, et al: TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 6: e23132, 2011.
28. Kitazoe M, Murata H, Futami J, et al: Protein transduction assisted by polyethylenimine-cationized carrier proteins. J Biochem 137: 693-701, 2005.
29. Murata H, Sakaguchi M, Futami J, et al: Denatured and reversibly cationized p53 readily enters cells and simultaneously folds to the functional protein in the cells. Biochemistry 45: 6124-6132, 2006.
30. Futami M, Watanabe Y, Asama T, et al: Uniformly cationized protein efficiently reaches the cytosol of mammalian cells. Bioconjug Chem 23: 2025-2031, 2012.
31. Schilling D, Thomas K, Nixdorff K, Vogel SN and Fenton MJ: Toll-like receptor 4 and Toll-IL?1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL?6 expression in macrophages. J Immunol 169: 5874-5880, 2002.
32. Loiarro M, Sette C, Gallo G, et al: Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin?1-dependent activation of NF?{kappa}B. J Biol Chem 280: 15809-15814, 2005.
33. Kaplan IM, Wadia JS and Dowdy SF: Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102: 247-253, 2005.
34. Bassi R, Giussani P, Anelli V, et al: HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 87: 23-33, 2008.
35. Kataoka K, Ono T, Murata H, et al: S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products. Oncol Lett 3: 1149-1153, 2012.
36. Hudson BI, Kalea AZ, Del Mar Arriero M, et al: Interaction of the RAGE cytoplasmic domain with diaphanous?1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 283: 34457-34468, 2008.
37. Yamamoto K, Murata H, Putranto EW, et al: DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells. Oncol Rep 29: 1073-1079, 2013.
38. Deane R, Singh I, Sagare AP, et al: A multimodal RAGE-specific inhibitor reduces amyloid ?mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122: 1377-1392, 2012.
39. Griffin WS, Sheng JG, McKenzie JE, et al: Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis. Neurobiol Aging 19: 401-405, 1998.
40. Mrak RE and Griffinbc WS: The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging 22: 915-922, 2001.